GE9:F:F-Genmab A/S (EUR)

COMMON STOCK | |

Last Closing

USD 241

Change

+3.60 (+1.52)%

Market Cap

USD 15.00B

Volume

221.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
NNND:F Tencent Holdings Ltd

+0.38 (+0.87%)

USD 416.07B
MATA:F Panasonic Corporation

+0.01 (+5.88%)

USD 20.38B
1CK:F CK Asset Holdings Limited

+0.14 (+4.20%)

USD 12.76B
0PY:F Paycom Soft

-0.25 (-0.16%)

USD 8.88B
2U4:F HICL Infrastructure PLC

+0.02 (+1.32%)

USD 2.83B
28MA:F CIELO SA SPONS. ADR 1

N/A

USD 2.57B
0LA:F ASSETMARK FIN. DL-001

N/A

USD 2.38B
CLN:F The City of London Investment ..

+0.05 (+0.97%)

USD 2.08B
R7I:F RENEWABLES INFRASTRUCTURE

-0.01 (-0.87%)

USD 1.89B
JR0:F Just Group plc

+0.03 (+1.90%)

USD 1.65B

ETFs Containing GE9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.14% N/A N/A 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.14% N/A N/A 26% F
Trailing 12 Months  
Capital Gain -33.37% N/A N/A 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.37% N/A N/A 19% F
Trailing 5 Years  
Capital Gain 32.60% N/A N/A 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.60% N/A N/A 50% F
Average Annual (5 Year Horizon)  
Capital Gain 8.27% N/A N/A 66% D+
Dividend Return 8.27% N/A N/A 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.19% N/A N/A 44% F
Risk Adjusted Return 28.32% N/A N/A 55% F
Market Capitalization 15.00B N/A N/A 89% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike